Taysha Gene Therapies (TSHA)
Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.
Something off on this page? Send us feedback.
Develops AAV-based gene therapies for severe monogenic CNS diseases, with TSHA-102 for Rett syndrome as the lead pivotal program. The company is pre-commercial, concentrated in the United States, and depends on clinical readouts, FDA feedback, manufacturing work, and capital access before any approved launch.
Develops AAV-based gene therapies for severe monogenic diseases of the central nervous system. The operating focus is TSHA-102, an intrathecal AAV9 program designed to deliver functional MECP2 for Rett syndrome, while other early-stage CNS programs remain secondary or partnership-dependent.
Started from a UT Southwestern gene-therapy collaboration and an initially broad pipeline, the company has narrowed around TSHA-102. Public materials list pivotal-stage development and several U.S., European, and U.K. regulatory designations for the program.
Remains pre-commercial, with no product-sales revenue and operations funded through equity, debt, and prior Astellas transactions. The business depends on clinical outcomes, FDA feedback, manufacturing readiness, capital access, and eventual commercialization capacity if approval is obtained.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | Initiate | Rating: — | |
| Jul 21, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $11 | Target: $13 |
| Jun 30, 2026 | Robert W. Baird | Target | Target: $12 | Target: $15 |
| Jun 23, 2026 | Pivotal Research | Target | Target: — | Target: $14 |
| Jan 6, 2026 | Raymond James | Target | Target: $9 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $455.4M · Total debt $55.6M · Total assets $470.4M · Shareholders' equity $387.3M
- Revenue
- $0
- Operating income
- −$47.3M
- Net income
- −$46.6M
No dividends on record.
| Institutions | ≈ 92.12% | 300.17M shares | |
|---|---|---|---|
| 216 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.63% | 31.38M shares | |
| 7 holders · as of Jul 10, 2026 | |||
| Adds to | 101.75% | ||
325.83M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.75%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Paul B. Manning1Insider10 percent owner | 7.86% | 25.60M | filed Jun 3, 2025 |
Avoro Capital Advisors LLCInstitution | 7.33% | 23.89M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 7.23% | 23.56M | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 6.97% | 22.71M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.35% | 20.69M | as of Jun 30, 2026 |
- Paul B. Manning's transaction reports restate only vehicles that traded; the 2025 ownership statement (25.60M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran | director, officer: President and Head of R&D | −200,000 | $6.24 |
| Apr 10, 2026 | Sukumar Nagendran | director, officer: President and Head of R&D | −200,000 | $4.46 |
| Feb 4, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −1,655 | $4.52 |
| Jan 26, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −23,849 | $4.61 |
| Jan 23, 2026 | Kamran Alam | officer: CHIEF FINANCIAL OFFICER | −78,968 | $4.75 |
- Neurogene
Closest Rett gene-therapy rival with NGN-401
- Acadia Pharmaceuticals
Commercial Rett incumbent through DAYBUE
- Ultragenyx Pharmaceutical
Rare neurogenetic and orphan-launch peer
- Sarepta Therapeutics
Commercial AAV genetic-medicine benchmark
- REGENXBIO
AAV platform and one-time rare-disease peer
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies | $5.28 | +2.45% | $1.61B | — | — | 293.9 | −100.0% |
| Neurogene | $33.68 | +0.30% | $514.7M | — | — | — | — |
| Acadia Pharmaceuticals | $26.41 | +0.02% | $4.52B | 11.9 | 29.5 | 4.0 | +16.4% |
| Ultragenyx Pharmaceutical | $15.65 | +0.26% | $1.44B | — | — | 2.0 | +28.5% |
| Sarepta Therapeutics | $21.07 | +1.20% | $2.13B | — | 36.2 | 1.1 | −34.3% |
| REGENXBIO | $8.15 | −0.12% | $407.4M | — | — | 2.3 | +405.7% |
| Median | 11.9 | 32.9 | 2.2 | +22.5% |